Clinical Trials
63
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (63 trials with phase data)• Click on a phase to view related trials
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
- Conditions
- Metachromatic Leukodystrophy (MLD)
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT07046338
- Locations
- 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
Combination Immunotherapy Targeting Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Antigen-specific CAR T, CTL and DCvac to treat melanoma.
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06739226
- Locations
- 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
- Conditions
- Autoimmune Diseases
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06435897
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Engineered Dendritic Cell Vaccines for Multiple Myeloma
- Conditions
- Multiple Myeloma or Plasmacytoma
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06435910
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇷🇺The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok, Russian Federation
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
- Conditions
- Multiple MyelomaPlasmacytoma
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06429150
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇷🇺Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
Dual-Target CAR-T Therapy Shows Promise for Glioblastoma with 24.5-Month Median Survival
A clinical trial combining PSMA and GD2 CAR-T cells achieved a median overall survival of 24.5 months in six patients with refractory or relapsed gliomas, significantly exceeding typical survival rates of 5-7 months.